Analysts expect MorphoSys AG Unsponsored ADR (NYSE:MOR) to post $10.53 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for MorphoSys’ earnings, with estimates ranging from $9.85 million to $11.20 million. MorphoSys reported sales of $9.69 million in the same quarter last year, which would suggest a positive year over year growth rate of 8.7%. The business is scheduled to report its next earnings results on Wednesday, August 7th.
On average, analysts expect that MorphoSys will report full year sales of $66.17 million for the current financial year, with estimates ranging from $57.12 million to $75.87 million. For the next financial year, analysts expect that the firm will report sales of $146.03 million, with estimates ranging from $88.48 million to $185.31 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover MorphoSys.
MorphoSys (NYSE:MOR) last posted its earnings results on Tuesday, May 7th. The company reported ($0.20) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.02. The company had revenue of $15.39 million for the quarter, compared to the consensus estimate of $10.34 million.
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Read More: Why do commodities matter?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.